Abnormal pattern of brain glucose metabolism in Parkinson’s disease: replication in three European cohorts
Rationale In Parkinson’s disease (PD), spatial covariance analysis of 18F-FDG PET data has consistently revealed a characteristic PD-related brain pattern (PDRP). By quantifying PDRP expression on a scan-by-scan basis, this technique allows objective assessment of disease activity in individual subjects. We provide a further validation of the PDRP by applying spatial covariance analysis to PD cohorts from the Netherlands (NL), Italy (IT), and Spain (SP). Methods The $ PDRP_{NL} $ was previously identified (17 controls, 19 PD) and its expression was determined in 19 healthy controls and 20 PD patients from the Netherlands. The $ PDRP_{IT} $ was identified in 20 controls and 20 “de-novo” PD patients from an Italian cohort. A further 24 controls and 18 “de-novo” Italian patients were used for validation. The $ PDRP_{SP} $ was identified in 19 controls and 19 PD patients from a Spanish cohort with late-stage PD. Thirty Spanish PD patients were used for validation. Patterns of the three centers were visually compared and then cross-validated. Furthermore, PDRP expression was determined in 8 patients with multiple system atrophy. Results A PDRP could be identified in each cohort. Each PDRP was characterized by relative hypermetabolism in the thalamus, putamen/pallidum, pons, cerebellum, and motor cortex. These changes co-varied with variable degrees of hypometabolism in posterior parietal, occipital, and frontal cortices. Frontal hypometabolism was less pronounced in “de-novo” PD subjects (Italian cohort). Occipital hypometabolism was more pronounced in late-stage PD subjects (Spanish cohort). $ PDRP_{IT} $, $ PDRP_{NL} $, and $ PDRP_{SP} $ were significantly expressed in PD patients compared with controls in validation cohorts from the same center (P < 0.0001), and maintained significance on cross-validation (P < 0.005). PDRP expression was absent in MSA. Conclusion The PDRP is a reproducible disease characteristic across PD populations and scanning platforms globally. Further study is needed to identify the topography of specific PD subtypes, and to identify and correct for center-specific effects..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
European journal of nuclear medicine & molecular imaging - 47(2019), 2 vom: 25. Nov., Seite 437-450 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meles, Sanne K. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s) 2019 |
|---|
| doi: |
10.1007/s00259-019-04570-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2041178205 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2041178205 | ||
| 003 | DE-627 | ||
| 005 | 20230517060109.0 | ||
| 007 | tu | ||
| 008 | 200819s2019 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00259-019-04570-7 |2 doi | |
| 035 | |a (DE-627)OLC2041178205 | ||
| 035 | |a (DE-He213)s00259-019-04570-7-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Meles, Sanne K. |e verfasserin |0 (orcid)0000-0002-5505-3527 |4 aut | |
| 245 | 1 | 0 | |a Abnormal pattern of brain glucose metabolism in Parkinson’s disease: replication in three European cohorts |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2019 | ||
| 520 | |a Rationale In Parkinson’s disease (PD), spatial covariance analysis of 18F-FDG PET data has consistently revealed a characteristic PD-related brain pattern (PDRP). By quantifying PDRP expression on a scan-by-scan basis, this technique allows objective assessment of disease activity in individual subjects. We provide a further validation of the PDRP by applying spatial covariance analysis to PD cohorts from the Netherlands (NL), Italy (IT), and Spain (SP). Methods The $ PDRP_{NL} $ was previously identified (17 controls, 19 PD) and its expression was determined in 19 healthy controls and 20 PD patients from the Netherlands. The $ PDRP_{IT} $ was identified in 20 controls and 20 “de-novo” PD patients from an Italian cohort. A further 24 controls and 18 “de-novo” Italian patients were used for validation. The $ PDRP_{SP} $ was identified in 19 controls and 19 PD patients from a Spanish cohort with late-stage PD. Thirty Spanish PD patients were used for validation. Patterns of the three centers were visually compared and then cross-validated. Furthermore, PDRP expression was determined in 8 patients with multiple system atrophy. Results A PDRP could be identified in each cohort. Each PDRP was characterized by relative hypermetabolism in the thalamus, putamen/pallidum, pons, cerebellum, and motor cortex. These changes co-varied with variable degrees of hypometabolism in posterior parietal, occipital, and frontal cortices. Frontal hypometabolism was less pronounced in “de-novo” PD subjects (Italian cohort). Occipital hypometabolism was more pronounced in late-stage PD subjects (Spanish cohort). $ PDRP_{IT} $, $ PDRP_{NL} $, and $ PDRP_{SP} $ were significantly expressed in PD patients compared with controls in validation cohorts from the same center (P < 0.0001), and maintained significance on cross-validation (P < 0.005). PDRP expression was absent in MSA. Conclusion The PDRP is a reproducible disease characteristic across PD populations and scanning platforms globally. Further study is needed to identify the topography of specific PD subtypes, and to identify and correct for center-specific effects. | ||
| 650 | 4 | |a F-FDG PET | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a Metabolic pattern | |
| 650 | 4 | |a Networks | |
| 700 | 1 | |a Renken, Remco J. |4 aut | |
| 700 | 1 | |a Pagani, Marco |4 aut | |
| 700 | 1 | |a Teune, L. K. |4 aut | |
| 700 | 1 | |a Arnaldi, Dario |4 aut | |
| 700 | 1 | |a Morbelli, Silvia |4 aut | |
| 700 | 1 | |a Nobili, Flavio |4 aut | |
| 700 | 1 | |a van Laar, Teus |4 aut | |
| 700 | 1 | |a Obeso, Jose A. |4 aut | |
| 700 | 1 | |a Rodríguez-Oroz, Maria C. |4 aut | |
| 700 | 1 | |a Leenders, Klaus L. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of nuclear medicine & molecular imaging |d Springer Berlin Heidelberg, 1976 |g 47(2019), 2 vom: 25. Nov., Seite 437-450 |w (DE-627)129097969 |w (DE-600)8236-3 |w (DE-576)014434644 |x 0340-6997 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2019 |g number:2 |g day:25 |g month:11 |g pages:437-450 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00259-019-04570-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4277 | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2019 |e 2 |b 25 |c 11 |h 437-450 | ||